

1 **Supplementary Methods for “Topical Timolol 0.5% Gel-Forming Solution for Erythema in**
2 **Rosacea: A Quantitative, Split-Face, Randomized, and Rater-Masked Pilot Clinical Trial”**

3

4 **Study Participants**

5 This study was approved by the Johns Hopkins University Institutional Review Board.
6 Participants provided written informed consent prior to participation. 12 adult participants
7 diagnosed by a dermatologist with rosacea involving frequent flushing and persistent facial
8 erythema were enrolled in Baltimore, Maryland. Additional inclusion criteria included age 18-65
9 years and willingness to not take any other medication during the study. Exclusion criteria
10 included history of taking any investigational drug within 30 days of study entry, use of systemic
11 or topical medications for rosacea including antibiotics within three weeks, current or planned
12 pregnancy, lactation, severe depression, and inability to provide informed consent. Participants
13 with history of hypersensitivity to beta-blockers, hypotension, bradycardia, congestive heart
14 failure, myocardial infarction, arrhythmia, asthma, and bronchospasm were excluded.

15 **Quantification of Erythema with Tristimulus Colorimetry**

16 At each visit, facial erythema was measured with the Chroma Meter CR-400 colorimeter
17 (Konica Minolta Sensing Americas, Inc., NJ, USA), which includes a D65 illuminant and
18 measuring head with 8 mm measurement area. The device was set to the Commission
19 Internationale de l'éclairage (CIE) $L^* a^* b^*$ mode. Participants were allowed to equilibrate by
20 resting for ≥ 15 minutes, and facial skin was cleansed with alcohol wipe prior to measurement.
21 For each measurement, the colorimeter was calibrated with a white reference panel and pressed
22 perpendicularly against the malar cheek (standardized to the intersection of the mid-pupillary

23 line and line drawn laterally from the ipsilateral nasal ala) with moderate pressure, with care
24 taken to minimize skin blanching. Averaged triplicate readings of L*, a*, and b* values were
25 obtained for each side of the face; L* indicates lightness ranging from 0 (black) to 100 (white),
26 a* indicates red-green chromaticity ranging from -60 (green) to +60 (red), and b* indicates blue-
27 yellow chromaticity ranging from -60 (blue) to +60 (yellow). Colorimeter-measured a* values
28 were used to represent erythema, with more positive values suggestive of increased erythema.

29 **Quantification of Erythema with Computer-Aided Image Analysis**

30 At each visit, cross-polarized photographs of both sides of the face were taken with a
31 Canon EOS 5D Mark II camera (Canon, Japan) and VISIA-CR Facial Imaging Booth (Canfield
32 Scientific, NJ, USA). The ImageJ software version 1.53a was used to convert each photograph to
33 separate CIE L*, a*, and b* 8-bit grayscale images. Pixel intensities of L*, a*, and b* images
34 ranged from 0 to 255 and cover the black-white, green-red, and blue-yellow gradients,
35 respectively. For each a* image, erythema was calculated by manually outlining the cheek
36 (encompassing the infraorbital, zygomatic, and mandibular regions) and measuring mean pixel
37 intensity, with more positive values indicative of increased erythema.

38 **Sample Size Calculation**

39 Sample size calculation was performed to detect a difference in colorimeter-measured a*
40 of 3.6 between affected and unaffected areas using the paired-sample t-test, assuming a standard
41 deviation of 3 based on previously published measurements. Type I error rate and power were set
42 at 0.05 and 0.8, respectively, yielding a required sample size of eight participants in each
43 treatment arm.

44 **Analysis of Change in Erythema with Mixed-Effects Models**

45 Mixed-effects models were used to characterize change in erythema over time, with
46 participants included as random effect. Timepoint of visit was treated as a categorical variable,
47 since change in erythema over time was expected to be nonlinear due to initiation of treatment on
48 the delayed treatment side at week 8 and discontinuation of treatment on both sides at week 16.
49 All analyses were performed with R version 4.0.0. Mixed-effects models were created using the
50 lme4 package. Comparisons of erythema at each timepoint to baseline were performed with t-
51 tests using Satterthwaite's method with Benjamini-Hochberg correction for multiple
52 comparisons. Visualizations were created with the ggplot2 package. For all analyses, two-sided
53 $P < .05$ was accepted as statistically significant.

54 **Imputation of Missing Data with Maximum Likelihood Method**

55 12 participants were initially enrolled, but four did not return after the baseline visit due
56 to lack of improvement (participant 01), scheduling difficulty (participant 10), and loss to contact
57 (participants 11, 12). The remaining eight participants who completed ≥ 2 visits were included in
58 the final data set (**Table S1**). Participant 07 withdrew after the second visit due to scheduling
59 difficulty. Only the first two visits of participant 06 were included in downstream analyses since
60 the third visit occurred six weeks later than scheduled. Missing data of participants 06 and 07
61 were treated as missing at random in mixed-effects models and estimated with the maximum
62 likelihood method based on outcomes of participants with similar baseline characteristics.